These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Bauersachs R; Gerlach HE; Heinken A; Hoffmann U; Langer F; Noppeney T; Pittrow D; Klotsche J; Rabe E Eur J Vasc Endovasc Surg; 2021 Aug; 62(2):241-249. PubMed ID: 34210599 [TBL] [Abstract][Full Text] [Related]
8. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Blondon M; Righini M; Bounameaux H; Veenstra DL Chest; 2012 Feb; 141(2):321-329. PubMed ID: 21757569 [TBL] [Abstract][Full Text] [Related]
9. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Werth S; Bauersachs R; Gerlach H; Rabe E; Schellong S; Beyer-Westendorf J J Thromb Thrombolysis; 2016 Aug; 42(2):197-204. PubMed ID: 26973347 [TBL] [Abstract][Full Text] [Related]
10. Isolated Great Saphenous Vein Thrombus Is Associated with High Rates of Complications regardless of Management. Kudlaty E; Oriowo B; Yang MJ; Go MR; Satiani B Ann Vasc Surg; 2017 Nov; 45():154-159. PubMed ID: 28600022 [TBL] [Abstract][Full Text] [Related]
11. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. Decousus H; Prandoni P; Mismetti P; Bauersachs RM; Boda Z; Brenner B; Laporte S; Matyas L; Middeldorp S; Sokurenko G; Leizorovicz A; N Engl J Med; 2010 Sep; 363(13):1222-32. PubMed ID: 20860504 [TBL] [Abstract][Full Text] [Related]
12. The safety of fondaparinux sodium for the treatment of venous thromboembolism. Mastroiacovo D; Sala G; Dentali F Expert Opin Drug Saf; 2016 Sep; 15(9):1259-65. PubMed ID: 27537418 [TBL] [Abstract][Full Text] [Related]
13. Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV). Camporese G; Di Micco P; Di Nisio M; Ageno W; Martini RC; Prandoni P; Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374272 [No Abstract] [Full Text] [Related]
14. [Epidemiologic and therapeutic advances in superficial venous thrombosis of the legs]. Bertoletti L; Frappé P; Leizorovicz A; Quéré I; Becker F; Moulin N; Decousus H Rev Prat; 2011 Nov; 61(9):1244-8. PubMed ID: 22308808 [TBL] [Abstract][Full Text] [Related]
15. Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)-rationale and protocol. Camporese G; Bernardi E; Bortoluzzi C; Noventa F; Simioni P; J Thromb Thrombolysis; 2024 Feb; 57(2):226-234. PubMed ID: 37932589 [TBL] [Abstract][Full Text] [Related]
16. Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study. Bozzato S; Rancan E; Ageno W Expert Opin Pharmacother; 2011 Apr; 12(5):835-7. PubMed ID: 21247361 [TBL] [Abstract][Full Text] [Related]
17. Superficial vein thrombosis: a current approach to management. Scott G; Mahdi AJ; Alikhan R Br J Haematol; 2015 Mar; 168(5):639-45. PubMed ID: 25521017 [TBL] [Abstract][Full Text] [Related]
18. Medical management of acute superficial vein thrombosis of the saphenous vein. Scovell SD; Ergul EA; Conrad MF J Vasc Surg Venous Lymphat Disord; 2018 Jan; 6(1):109-117. PubMed ID: 29097174 [TBL] [Abstract][Full Text] [Related]